Published on
March 19, 2023
- 23:00 GMT
Novartis shares Zolgensma long-term data demonstrating sustained durability up to 7.5 years post-dosing; 100% achievement of all ...
Children in LT-001 treated after SMA symptom onset maintained or achieved additional milestones up to 7.5 years post one-time intravenous infusion All children (100%) in the presymptomatic intravenous cohort of LT-002 maintained or achieved all assessed …
Distribution channels:
Healthcare & Pharmaceuticals Industry, Media, Advertising & PR
...
